Coya Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Coya Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Coya Therapeutics, Inc. Common Stock (COYA) has a Cash Flow-to-Debt Ratio of -3.39x as of June 2026, meaning its operating cash flow of $-13.67 Billion could theoretically repay -3% of its total liabilities ($4.03 Billion) in one year. Check how high is Coya Therapeutics, Inc. Common Stock's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Coya Therapeutics, Inc. Common Stock (2020–2025)
Cash flow-to-debt ratio of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. Historical debt coverage capacity for Coya Therapeutics, Inc. Common Stock across 6 annual periods. Check Coya Therapeutics, Inc. Common Stock cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Coya Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2020–2025)
Coya Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Coya Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Coya Therapeutics, Inc. Common Stock cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.55x | $-10.74 Million | $6.92 Million | ▲ +28.1% |
| 2024 | -2.16x | $-10.29 Million | $4.77 Million | ▼ -8.5% |
| 2023 | -1.99x | $-11.19 Million | $5.63 Million | ▼ -361.2% |
| 2022 | -0.43x | $-7.24 Million | $16.79 Million | ▲ +87.3% |
| 2021 | -3.40x | $-3.90 Million | $1.15 Million | ▼ -288.4% |
| 2020 | -0.88x | $-391.27K | $447.12K | — |